EMA Authorised: Zeposia (ozanimod hydrochloride) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA has authorised Zeposia (ozanimod hydrochloride) for relapsing-remitting multiple sclerosis and ulcerative colitis; the marketing authorisation holder is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Ulcerative Colitis

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting;Colitis, Ulcerative. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 15/01/2026